Metsera, INC DEF 14A proxy statements

Metsera's Board unanimously recommends an amended merger agreement with Pfizer, increasing the cash consideration to $65.60 per share and total potential value to $86.25 per share, following a competitive bidding process and regulatory scrutiny.

Metsera's Board of Directors has determined that Novo Nordisk's revised acquisition proposal, valuing the company at up to $86.20 per share, constitutes a superior offer compared to Pfizer's latest proposal.

Metsera, Inc. issued a statement refuting Pfizer's litigation, asserting it is an attempt to lower the acquisition price amidst a competing proposal from Novo Nordisk.

Metsera, Inc. has issued a statement disagreeing with Pfizer's litigation allegations, vowing to address them in court.

Metsera's Board of Directors has deemed an unsolicited acquisition proposal from Novo Nordisk, valued at up to $77.75 per share, a 'Superior Company Proposal' compared to its existing merger agreement with Pfizer.

Metsera's Board unanimously recommends stockholders approve the merger with Pfizer for $47.50 cash plus a contingent value right up to $22.50 per share, valuing the deal at a 110% premium.